Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 811

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 811
---
 Securities Act, and is, therefore, unenforceable. II-1

Item 21. Exhibits and Financial Statements Schedules (a) Exhibits The following exhibits are filed as part of this Registration Statement:

| Exhibit 
 Number  
 2.1     
 2.2     |     | Description of Document                                                                                                                                                                                                                                                         
 Agreement and Plan of Merger, dated as of November 4, 2024, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus forming a part of this Registration Statement).                     
 Amendment No. 1 to Agreement and Plan of Merger, dated as of January 30, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement).  |
|:--------|:----|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.3     |     | Amendment No. 2 to Agreement and Plan of Merger, dated as of February 17, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement). |
| 2.4     |     | Amendment No. 3 to Agreement and Plan of Merger, dated as of May 5, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement).       |
| 2.5     |     | Amendment No. 4 to Agreement and Plan of Merger, dated as of June 5, 2025, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included in Annex A to the proxy statement/prospectus forming a part of this Registration Statement).      |
| 3.1**   |     | Amended and Restated Articles of Association of NLS Pharmaceutics Ltd. (filed as Exhibit 99.1 to Form 6-K (File No.